Geodon in Weight Loss Study for Bipolar Disorders

Exclusion Criteria

• •One of the following DSM-IV Axis I diagnoses: delirium, dementia, amnestic and other cognitive disorders, schizophrenia, anorexia nervosa or bulimia, or substance abuse or dependence (active within the last month), abuse of illicit drugs (excluding marijuana) within the past month
• •Antisocial personality disorder
• •Medical complications of obesity such as diabetes, hypertension, hyperlipidemia, and cardiovascular disease unless followed by their own general medical practitioner who authorizes their participation in the trial, and continues to follow them medically and make necessary adjustments of concurrent antidiabetic, antihypertensive, antihyperlipidemic agents during the trial;
• •Item 10 (Suicidal Thoughts) on the MADRS greater than or equal to 4
• •Suicide attempt within the past three months
• •Obesity of endocrine origin
• •Seizure disorders
• •Progressive neurologic or systemic disorders; HIV
• •Other serious illnesses such as cardiac, hepatic (including cirrhosis), renal, respiratory, neurologic, or hematologic disease or glaucoma
• •Hypothyroidism or hyperthyroidism unless adequately treated with TSH no more than 10% above or below the limits of the normal range.
• •Administration of any investigational drug within 30 days prior to screening
• •Allergy or hypersensitivity to ziprasidone
• •Administration of clozapine in the prior three months
• •Pregnancy within the past six months
• •Patients will be discontinued from the study should they develop any significant adverse side effects that cannot be managed by dosage adjustment